NCCN  ||| S:0 E:5 ||| NNP
molecular  ||| S:5 E:15 ||| VBZ
testing  ||| S:15 E:23 ||| VBG
white  ||| S:23 E:29 ||| JJ
paper ||| S:29 E:34 ||| NN
:  ||| S:34 E:36 ||| :
effectiveness ||| S:36 E:49 ||| NN
,  ||| S:49 E:51 ||| ,
efficiency ||| S:51 E:61 ||| NN
,  ||| S:61 E:63 ||| ,
and  ||| S:63 E:67 ||| CC
reimbursement  ||| S:67 E:81 ||| JJ
Personalized  ||| S:81 E:94 ||| JJ
medicine  ||| S:94 E:103 ||| NN
in  ||| S:103 E:106 ||| IN
oncology  ||| S:106 E:115 ||| NN
is  ||| S:115 E:118 ||| VBZ
maturing  ||| S:118 E:127 ||| VBG
and  ||| S:127 E:131 ||| CC
evolving  ||| S:131 E:140 ||| VBG
rapidly ||| S:140 E:147 ||| RB
,  ||| S:147 E:149 ||| ,
and  ||| S:149 E:153 ||| CC
the  ||| S:153 E:157 ||| DT
use  ||| S:157 E:161 ||| NN
of  ||| S:161 E:164 ||| IN
molecular  ||| S:164 E:174 ||| JJ
biomarkers  ||| S:174 E:185 ||| NN
in  ||| S:185 E:188 ||| IN
clinical  ||| S:188 E:197 ||| JJ
decision-making  ||| S:197 E:213 ||| NN
is  ||| S:213 E:216 ||| VBZ
growing ||| S:216 E:223 ||| VBG
.  ||| S:223 E:225 ||| .
This  ||| S:225 E:230 ||| DT
raises  ||| S:230 E:237 ||| VBZ
important  ||| S:237 E:247 ||| JJ
issues  ||| S:247 E:254 ||| NNS
regarding  ||| S:254 E:264 ||| VBG
the  ||| S:264 E:268 ||| DT
safe ||| S:268 E:272 ||| JJ
,  ||| S:272 E:274 ||| ,
effective ||| S:274 E:283 ||| JJ
,  ||| S:283 E:285 ||| ,
and  ||| S:285 E:289 ||| CC
efficient  ||| S:289 E:299 ||| JJ
deployment  ||| S:299 E:310 ||| NN
of  ||| S:310 E:313 ||| IN
molecular  ||| S:313 E:323 ||| JJ
tests  ||| S:323 E:329 ||| NNS
to  ||| S:329 E:332 ||| TO
guide  ||| S:332 E:338 ||| VB
appropriate  ||| S:338 E:350 ||| JJ
care ||| S:350 E:354 ||| NN
,  ||| S:354 E:356 ||| ,
specifically  ||| S:356 E:369 ||| RB
regarding  ||| S:369 E:379 ||| VBG
laboratory-developed  ||| S:379 E:400 ||| JJ
tests  ||| S:400 E:406 ||| NNS
and  ||| S:406 E:410 ||| CC
companion  ||| S:410 E:420 ||| NN
diagnostics ||| S:420 E:431 ||| NNS
.  ||| S:431 E:433 ||| .
In  ||| S:433 E:436 ||| IN
May  ||| S:436 E:440 ||| NNP
2011 ||| S:440 E:444 ||| CD
,  ||| S:444 E:446 ||| ,
NCCN  ||| S:446 E:451 ||| NNP
assembled  ||| S:451 E:461 ||| VBD
a  ||| S:461 E:463 ||| DT
work  ||| S:463 E:468 ||| NN
group  ||| S:468 E:474 ||| NN
composed  ||| S:474 E:483 ||| VBN
of  ||| S:483 E:486 ||| IN
thought  ||| S:486 E:494 ||| NN
leaders  ||| S:494 E:502 ||| NNS
from  ||| S:502 E:507 ||| IN
NCCN  ||| S:507 E:512 ||| NNP
Member  ||| S:512 E:519 ||| NNP
Institutions  ||| S:519 E:532 ||| NNPS
and  ||| S:532 E:536 ||| CC
other  ||| S:536 E:542 ||| JJ
organizations  ||| S:542 E:556 ||| NNS
to  ||| S:556 E:559 ||| TO
identify  ||| S:559 E:568 ||| VB
challenges  ||| S:568 E:579 ||| NNS
and  ||| S:579 E:583 ||| CC
provide  ||| S:583 E:591 ||| VB
guidance  ||| S:591 E:600 ||| VBN
regarding  ||| S:600 E:610 ||| VBG
molecular  ||| S:610 E:620 ||| JJ
testing  ||| S:620 E:628 ||| NN
in  ||| S:628 E:631 ||| IN
oncology  ||| S:631 E:640 ||| NN
and  ||| S:640 E:644 ||| CC
its  ||| S:644 E:648 ||| PRP$
corresponding  ||| S:648 E:662 ||| JJ
utility  ||| S:662 E:670 ||| NN
from  ||| S:670 E:675 ||| IN
clinical ||| S:675 E:683 ||| JJ
,  ||| S:683 E:685 ||| ,
scientific ||| S:685 E:695 ||| JJ
,  ||| S:695 E:697 ||| ,
and  ||| S:697 E:701 ||| CC
coverage  ||| S:701 E:710 ||| NN
policy  ||| S:710 E:717 ||| NN
standpoints ||| S:717 E:728 ||| NN
.  ||| S:728 E:730 ||| .
The  ||| S:730 E:734 ||| DT
NCCN  ||| S:734 E:739 ||| NNP
Molecular  ||| S:739 E:749 ||| NNP
Testing  ||| S:749 E:757 ||| NNP
Work  ||| S:757 E:762 ||| NNP
Group  ||| S:762 E:768 ||| NNP
identified  ||| S:768 E:779 ||| VBD
challenges  ||| S:779 E:790 ||| NNS
surrounding  ||| S:790 E:802 ||| VBG
molecular  ||| S:802 E:812 ||| JJ
testing ||| S:812 E:819 ||| NN
,  ||| S:819 E:821 ||| ,
including  ||| S:821 E:831 ||| VBG
health  ||| S:831 E:838 ||| NN
care  ||| S:838 E:843 ||| NN
provider  ||| S:843 E:852 ||| NN
knowledge ||| S:852 E:861 ||| NN
,  ||| S:861 E:863 ||| ,
determining  ||| S:863 E:875 ||| VBG
clinical  ||| S:875 E:884 ||| JJ
utility ||| S:884 E:891 ||| NN
,  ||| S:891 E:893 ||| ,
coding  ||| S:893 E:900 ||| NN
and  ||| S:900 E:904 ||| CC
billing  ||| S:904 E:912 ||| NN
for  ||| S:912 E:916 ||| IN
molecular  ||| S:916 E:926 ||| JJ
tests ||| S:926 E:931 ||| NNS
,  ||| S:931 E:933 ||| ,
maintaining  ||| S:933 E:945 ||| VBG
clinical  ||| S:945 E:954 ||| JJ
and  ||| S:954 E:958 ||| CC
analytic  ||| S:958 E:967 ||| JJ
validity  ||| S:967 E:976 ||| NN
of  ||| S:976 E:979 ||| IN
molecular  ||| S:979 E:989 ||| JJ
tests ||| S:989 E:994 ||| NNS
,  ||| S:994 E:996 ||| ,
efficient  ||| S:996 E:1006 ||| JJ
use  ||| S:1006 E:1010 ||| NN
of  ||| S:1010 E:1013 ||| IN
specimens ||| S:1013 E:1022 ||| NNS
,  ||| S:1022 E:1024 ||| ,
and  ||| S:1024 E:1028 ||| CC
building  ||| S:1028 E:1037 ||| VBG
clinical  ||| S:1037 E:1046 ||| JJ
evidence ||| S:1046 E:1054 ||| NN
.  ||| S:1054 E:1056 ||| .
